Remove 2019 Remove Physicians Remove Safety
article thumbnail

Is DTC effective?

World of DTC Marketing

During the first quarter of 2020, the number of telehealth visits increased by 50%, compared with the same period in 2019, with a 154% increase in visits noted in surveillance week 13 in 2020, compared with the same period in 2019. For example, what percentage of patients experienced suicidal thoughts?

article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

Members of a multidisciplinary care team may include physicians, nurses, pharmacists, radiologists, dieticians…the list goes on. 2 In 2019, there were 7 potential family caregivers per older adult. February 2019. But one key member is often omitted: the patient’s caregiver. Centers for Disease Control and Prevention.

Pharma 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Look Into Telehealth in 2021 and Beyond

Pharma Marketing Network

Billion in 2019 and Expected to Reach USD 171.81 Physicians and patients raise legitimate questions and concerns about the safety, effectiveness, and accessibility of telehealth. Wearable technology allows physicians to check in on the health of their patients in between physical office visits. over the Forecast Period.”.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires.

article thumbnail

Lupkynis approved for the treatment of LN in the EU and UK

Pharmaceutical Technology

However, the lack of in-person administration by physicians will likely also impact patient compliance. Adoption of Lupkynis in the European market will depend largely on pricing as well as reception by physicians.

article thumbnail

Gene therapy: a radical pharmaceutical revolution

European Pharmaceutical Review

Considerable progress has been made in other areas including enhancing safety, improving treatment administration and patient monitoring systems and implementing innovative pricing strategies – all with the goal of providing timely access to eligible patients who can benefit from these treatments. 2019; 70:273–288. cited 2023August].

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

The week 16 data of lebrikizumab […] points towards a drug with robust efficacy with hardly any safety trade-offs. The FDA granted lebrikizumab Fast Track designation in December 2019. He explained just how promising the recent trial’s maintenance data compared to short-term data results are. Thyssen, MD, Ph.D.